Synthesis and antibacterial activity of potent heterocyclic oxazolidinones and the identification of RBx 8700

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 24, 2007, Pages 6714-6719

  Rudra, Sonali ^a   Yadav, Ajay ^a   Raja Rao, A V S ^a   Srinivas, A S S V ^a   Pandya, Manisha ^a   Bhateja, Pragya ^a   Mathur, Tarun ^a   Malhotra, Sunita ^a   Rattan, Ashok ^a   Salman, Mohammed ^a   Mehta, Anita ^a   Cliffe, Ian A ^a   Das, Biswajit ^a  

^a RANBAXY LABORATORIES LTD   (India)

Author keywords

Antibacterial; Nitrofuran; Nitrothiophene; Oxazolidinone; Ranbezolid; RBx 7644; RBx 8700

Indexed keywords

ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; LINEZOLID; OXAZOLIDINONE DERIVATIVE; PIPERAZINE DERIVATIVE; RANBEZOLID; RBX 8700; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DIASTEREOISOMER; DRUG POTENCY; DRUG SYNTHESIS; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STEREOSPECIFICITY; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; STRUCTURE ACTIVITY RELATION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; ENTEROCOCCUS FAECIUM; MOLECULAR STRUCTURE; OXAZOLIDINONES; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 36049016470     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.10.061     Document Type: Article

References (20)

1. Brickner S.J., Hutchinson D.K., Barbachyn M.R., Manninen P.R., Ulanowicz D.A., Gammon S.A., Grega K.C., Hendges S.K., Toops D.S., Ford C.W., and Zurenko G.E. J. Med. Chem. 39 (1996) 673
2. Barbachyn M.R., and Ford C.W. Angew. Chem. Int. Ed. 42 (2003) 2010
3. Aoki H., Ke L., Poppe S.M., Poel T.J., Weaver E.A., Gadwood R.C., Thomas R.C., Shinabarger D.L., and Ganoza M.C. Antimicrob. Agents Chemother. 46 (2002) 1080 and references cited therein
4. Mehta, A.; Arora, S. K.; Das, B.; Ray, A.; Rudra, S.; Rattan, A. PCT WO 02/06278, 2002.
5. Mehta, A.; Arora, S. K.; Das, B.; Ray, A.; Rudra, S.; Rattan, A. PCT WO 03/007870, 2003.
6. Mehta, A.; Rudra, S.; Rao, A. V. S.; Das, B.; Ray, A.; Srinivas, A. S. S. V.; Arora, S. K.; Rattan, A. PCT WO 03/008389, 2003.
7. Mehta, A.; Rudra, S.; Raja Rao, A. V. S.; Yadav, A.; Rattan, A. PCT WO 04/014392, 2004.
8. Salman, M.; Das, B.; Rudra, S.; Yadav, A.; Rattan, A. PCT WO 05/082899, 2005.
9. Das B., Rudra S., Yadav A., Ray A., Raja Rao A.V.S., Srinivas A.S.S.V., Soni A., Saini S., Shukla S., Pandya M., Bhateja P., Malhotra S., Mathur T., Arora S.K., Rattan A., and Mehta A. Bioorg. Med. Chem. Lett. 15 (2005) 4261
10. + = 418.3 [100%]; HPLC purity = 98.44%; mp = 171-174 °C.
11. Hutchinson, D. K.; Brickner, S. J.; Gammill, R. V.; Patel, M. V. U.S. Patent 5700799, 1997.
12. Harris M.C., Geis O., and Buchwald S.L. J. Org. Chem. 64 (1999) 6019
13. Wolfe J.P., and Buchwald S.L. J. Org. Chem. 65 (2000) 1144
14. In vitro: Minimum inhibitory concentration (MIC) was determined by an agar dilution method (NCCLS methodology) using doubling dilutions in cation adjusted Mueller Hinton agar over a concentration range of 16-0.015 μg/ml with incubation in air at 35 °C for 24 h.
15. 16 method on day 7 post infection.
16. Finney D.J. The Spearman Karber Method: Statistical method in biological assay (1952), Charles Griffin and Company, London pp 524-530
17. Lohray B.B., Lohray V.B., Srivastava B.K., Gupta S., Solanki M., Pandya P., and Kapadnis P. Bioorg. Med. Chem. Lett. 16 (2006) 1557
18. Sood, R.; Rao, M.; Malhotra, S.; Bhaduria, T.; Malhotra, S.; Bhateja, P.; Pandya, M.; Rudra, S.; Das, B.; Upadhyay, D.; Rattan, A. Abstract of papers, 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA, American Society for Microbiology: Washington, DC, 2004; Abstract F1414.
19. Sood R., Rao M., Singhal S., and Rattan A. Int. J. Antimicrob. Agents 25 (2005) 464
20. Sood R., Bhaduria T., Rao M., Gautam R., Malhotra S., Barman T.K., Upadhyay D., and Rattan A. Infect. Disord. Drug Targets 6 (2006) 343